FINWIRES · TerminalLIVE
FINWIRES

亞洲生質燃料市場最新動態:受令吉走軟、原油價格上漲及厄爾尼諾現象風險影響,期貨價格小幅走高

-- 週五,馬來西亞棕櫚油期貨價格小幅上漲,受令吉走軟和原油價格上漲的支撐,生物柴油更具吸引力,同時厄爾尼諾現象風險加劇以及生物柴油混合比例上升也推高了棕櫚油價格。 週四價格回落後,馬來西亞衍生性商品交易所5月棕櫚油期貨合約上漲0.22%,報每噸4,515令吉(1,139.29美元)。 6月合約也上漲0.22%,報每噸4,562令吉。 兩份合約本週累計上漲近2%,扭轉了先前連續兩週的跌勢。 然而,儘管令吉走軟(過去一周下跌0.32%),且原油價格飆升(根據Trading Economics數據顯示,布蘭特原油期貨價格觸及每桶105.98美元),棕櫚油價格週五仍出現下跌。 此外,馬來西亞棕櫚油理事會週五表示,預計短期內棕櫚油價格將維持在每噸4,500令吉以上。理事會將此歸因於潛在的厄爾尼諾現象風險,該風險可能影響棕櫚油供應,以及馬來西亞正逐步提高生物柴油的摻混比例,從目前的B10轉向B15。理事會表示,此舉每年可額外吸收100萬至150萬噸棕櫚油。 理事會還表示,印尼和泰國也正在推行類似的生物柴油計劃,兩國都提高了生物柴油的摻混比例,預計這將進一步加劇短期內的市場供應緊張。 據價格報告機構MySteel稱,由於中東局勢短期內不太可能緩解,且原油價格再次飆升,棕櫚油作為「生物柴油原料」的地位得到鞏固,從而推高了期貨價格。

Related Articles

Research

Research Alert: CFRA Keeps Buy Opinion On Shares Of The Hartford Insurance Group, Inc.

CFRA, an independent research provider, has providedwith the following research alert. Analysts at CFRA have summarized their opinion as follows:We trim our 12-month target price by $8 to $155, valuing HIG shares at 11.3x our 2026 operating EPS estimate of $13.75 (cut by $0.45) and at 10.6x our 2027 EPS estimate of $14.65 (cut by $0.30), vs. the shares' one-year average forward multiple of 10.3x and peer average of 13x. Q1 EPS of $3.09 vs. $2.20 a year ago missed our $3.60 estimate and $3.39 consensus view. Operating revenue growth of 6.2% was in line with our 6%-10% forecast, amid 5.3% earned premium growth, 13% higher net investment income, and 7.9% fee revenue growth. Q1 written premium growth of 4% and full-year 2025 growth of 7% bode well for 2026 revenue trends as premiums are earned. Underwriting results improved significantly, with Personal Lines combined ratio improving to 87.7% from 106.1% and underlying combined ratio to 85.0% from 89.7%. Business Insurance combined ratio was stable at 94.8%. Weighing the Q1 EPS miss with HIG's decent top-line growth and discounted valuation to peers, we view the shares as undervalued.

$HIG
Research

Research Alert: CFRA Keeps Strong Buy Opinion On Shares Of Baker Hughes

CFRA, an independent research provider, has providedwith the following research alert. Analysts at CFRA have summarized their opinion as follows:We raise our 12-month target price by $14 to $82, reflecting a combination of our sum-of-the-parts (SOTP) and DCF models. For our SOTP model, we presume the oilfield services business (about 50% of BKR's franchise) to be valued at about 10x projected 2027 EBITDA (in line with major peers) and its industrial energy technology business (the other 50%) valued at 14x projected 2027 EBITDA (in line with the peer median). This blended approach, yielding a 12x multiple, implies a value of $73 per share. Meanwhile, our DCF model, using medium-term free cash flow growth of 5% per year, terminal growth of 2.5%, discounted at a WACC of 6.3%, yields intrinsic value of $91 per share. We cut our 2026 EPS estimate by $0.47 to $2.48, but we raise 2027's by $0.07 to $3.24. We acknowledge that the oilfield services business is likely to struggle in 2026 owing to the U.S.-Iran conflict, but the IET business appears quite robust and likely to be a source of both accelerating revenue growth and margins.

$BKR
Research

Research Alert: CFRA Maintains Hold Opinion In Shares Of Wab

CFRA, an independent research provider, has providedwith the following research alert. Analysts at CFRA have summarized their opinion as follows:We lift our 12-month target to $285 from $275 following WAB's Q1 earnings print, valuing shares at 24.2x our 2027 EPS outlook of $11.76 (revised from $11.46; 2026 EPS estimate up to $10.57 from $10.50), a slight premium to WAB's long-term historical multiple average given structural improvements in earnings quality. While we are cautious on signs of overcapacity in the freight market, an elevated order backlog (12-month sits at over $9 billion), internal initiatives to shore up margins, and potential synergies from M&A activity positions WAB to continue growing earnings at double-digit rates in 2026-2027, in our view. Despite tariff-related cost pressures, WAB has done a commendable job of defending margins via a mix of pricing, lean manufacturing, and pruning of lower-profit operations. Q1 results were mixed but overall positive, in our view. We maintain our Hold recommendation on shares.

$WAB